U. Rebmann
About
U. Rebmann is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, U. Rebmann has authored 34 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 11 papers in Surgery and 10 papers in Oncology. Recurrent topics in U. Rebmann's work include Renal cell carcinoma treatment (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Pelvic floor disorders treatments (4 papers). U. Rebmann is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Pelvic floor disorders treatments (4 papers). U. Rebmann collaborates with scholars based in Germany, Italy and Norway. U. Rebmann's co-authors include H. Heynemann, Michael Stöckle, N. Willich, Alessandra Siegmann, Stephan Störkel, Horst Jürgen Feldmann, T. Kälble, L. Weißbach, Kurt Miller and Reinhard Golz and has published in prestigious journals such as Journal of Clinical Oncology, NeuroImage and The Journal of Urology.
In The Last Decade
U. Rebmann
31 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| U. Rebmann Germany | 15 | 896 | 363 | 307 | 210 | 192 | 34 | 1.4k | ||
| A Tizzani Italy | 22 | 731 0.8× | 297 0.8× | 766 2.5× | 50 0.2× | 221 1.2× | 97 | 1.8k | ||
| Vito Cucchiara Italy | 27 | 1.3k 1.4× | 248 0.7× | 524 1.7× | 53 0.3× | 327 1.7× | 69 | 1.9k | ||
| Wolfgang Loidl Austria | 23 | 1.5k 1.7× | 448 1.2× | 338 1.1× | 80 0.4× | 143 0.7× | 71 | 1.9k | ||
| Sarat Chander Australia | 20 | 1.1k 1.3× | 429 1.2× | 507 1.7× | 427 2.0× | 133 0.7× | 72 | 1.7k | ||
| Giulio Francolini Italy | 22 | 796 0.9× | 312 0.9× | 226 0.7× | 340 1.6× | 51 0.3× | 120 | 1.3k | ||
| John Tsihlias Canada | 12 | 586 0.7× | 472 1.3× | 244 0.8× | 66 0.3× | 107 0.6× | 14 | 1.2k | ||
| Hedy Mameghan Australia | 20 | 602 0.7× | 254 0.7× | 415 1.4× | 198 0.9× | 48 0.3× | 54 | 1.2k | ||
| Jiřı́ Petera Czechia | 18 | 369 0.4× | 344 0.9× | 291 0.9× | 102 0.5× | 61 0.3× | 108 | 969 | ||
| Najeeb Mohideen United States | 17 | 1.0k 1.2× | 380 1.0× | 302 1.0× | 369 1.8× | 42 0.2× | 36 | 1.4k | ||
| Alberto Martini Italy | 24 | 1.2k 1.3× | 376 1.0× | 681 2.2× | 29 0.1× | 367 1.9× | 145 | 1.9k |
Countries citing papers authored by U. Rebmann
Since
Specialization
Citations
This map shows the geographic impact of U. Rebmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Rebmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Rebmann more than expected).
Fields of papers citing papers by U. Rebmann
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by U. Rebmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Rebmann. The network helps show where U. Rebmann may publish in the future.
Co-authorship network of co-authors of U. Rebmann
This figure shows the co-authorship network connecting the top 25 collaborators of U. Rebmann. A scholar is included among the top collaborators of U. Rebmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Rebmann. U. Rebmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Holze, Sigrun, Meinhard Mende, Lutz Gansera, et al.. (2019). Comparison of various continence definitions in a large group of patients undergoing radical prostatectomy: a multicentre, prospective study. BMC Urology. 19(1). 70–70.
2.
Barbagli, Guido, Axel Heidenreich, Dirk Fahlenkamp, et al.. (2017). Results of Use of Tissue-Engineered Autologous Oral Mucosa Graft for Urethral Reconstruction: A Multicenter, Prospective, Observational Trial. EBioMedicine. 23. 185–192.
3.
Köhler, Norbert, Lutz Gansera, Sigrun Holze, et al.. (2014). Cancer-related fatigue in patients before and after radical prostatectomy. Results of a prospective multi-centre study. Supportive Care in Cancer. 22(11). 2883–2889.
4.
Bergmann, Lothar, Thomas Steiner, Peter J. Goebell, et al.. (2014). Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients (Pts) with Advanced or Metastatic Renal Cell Carcinoma (A/Mrcc) in Routine Clinical Practice. Annals of Oncology. 25. iv296–iv296.
5.
Bottke, Dirk, Christian Bronner, Ulrich K. Steiner, et al.. (2013). 192 The 10-years follow-up of the ARO 96-02/AUO AP 09/95 trial on adjuvant radiotherapy (ART) versus wait-and-see (WS) after prostatectomy for pT3 cancer – subgroup analysis. European Urology Supplements. 12(1). e192–e193.
6.
Wiegel, Thomas, Dirk Bottke, Detlef Bartkowiak, et al.. (2013). Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up.. Journal of Clinical Oncology. 31(6_suppl). 4–4.
7.
Baudewig, Jürgen, et al.. (2013). Monitoring brain activation changes in the early postoperative period after radical prostatectomy using fMRI. NeuroImage. 78. 1–6.
8.
Holze, Sigrun, Lutz Gansera, U. Rebmann, et al.. (2012). Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach. International Journal of Impotence Research. 24(4). 155–160.
9.
Rebmann, U., et al.. (2011). Gibt es den symptomlosen Nierenstein?. Aktuelle Urologie. 42(6). 374–377.
10.
Gansera, Lutz, Jens‐Uwe Stolzenburg, U. Rebmann, et al.. (2011). Early continence in patients with localized prostate cancer. A comparison between open retropubic (RRPE) and endoscopic extraperitoneal radical prostatectomy (EERPE). Urologic Oncology Seminars and Original Investigations. 30(6). 798–803.
11.
Wiegel, Thomas, Dirk Bottke, Ursula Steiner, et al.. (2009). Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95. Journal of Clinical Oncology. 27(18). 2924–2930.
12.
Schreiber, M. R., et al.. (2008). Spontane perirenale Hämatome bei Patienten mit Koagulopathien oder unter Antikoagulanzientherapie. Aktuelle Urologie. 39(3). 215–218.
13.
Atzpodien, Jens, Hartmut Kirchner, Udo Jonas, et al.. (2004). Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Journal of Clinical Oncology. 22(7). 1188–1194.
14.
Bilkenroth, Udo, Helge Täubert, Dagmar Riemann, et al.. (2001). Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. International Journal of Cancer. 92(4). 577–582.
15.
Albers, Peter, Roswitha Siener, Michael Hartmann, et al.. (1999). Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the German multicenter trial. International Journal of Cancer. 83(6). 828–830.
16.
Weidner, W., I. Schroeder‐Printzen, U. Rebmann, et al.. (1999). RANDOMIZED PROSEPECTIVE PLACEBO-CONROLLED THERAPY OF PEYRONIE'S DISEASE (IPP) WITH POTABAR (AMINOBENZOATE POTASSIUM). The Journal of Urology. 205–205.
17.
Oberhoff, C., B Neri, D. Amadori, et al.. (1998). Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Annals of Oncology. 9(3). 255–260.
18.
Clausen, Tobias, et al.. (1997). Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney. Journal of Cancer Research and Clinical Oncology. 123(7). 402–406.
19.
Atzpodien, Jens, E Lopez Hänninen, H. Kirchner, et al.. (1995). Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.. Journal of Clinical Oncology. 13(2). 497–501.
20.
Rebmann, U., et al.. (1990). [Cisplatin-induced nephrotoxic side effects of cytostatic chemotherapy of testicular tumors].. PubMed. 23(2). 83–5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A Tizzani Breakdown of academic impact, for papers by Vito Cucchiara Breakdown of academic impact, for papers by Wolfgang Loidl Breakdown of academic impact, for papers by Sarat Chander Breakdown of academic impact, for papers by Giulio Francolini Breakdown of academic impact, for papers by John Tsihlias Breakdown of academic impact, for papers by Hedy Mameghan Breakdown of academic impact, for papers by Jiřı́ Petera Breakdown of academic impact, for papers by Najeeb Mohideen Breakdown of academic impact, for papers by Alberto Martini